nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimozide—OPRK1—Peptide ligand-binding receptors—CXCL11—nasal cavity cancer	0.0282	0.0282	CbGpPWpGaD
Pimozide—OPRM1—Peptide ligand-binding receptors—CXCL11—nasal cavity cancer	0.0238	0.0238	CbGpPWpGaD
Pimozide—OPRK1—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0238	0.0238	CbGpPWpGaD
Pimozide—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.0225	0.0225	CbGpPWpGaD
Pimozide—OPRM1—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0201	0.0201	CbGpPWpGaD
Pimozide—DRD3—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0199	0.0199	CbGpPWpGaD
Pimozide—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0189	0.0189	CbGpPWpGaD
Pimozide—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0186	0.0186	CbGpPWpGaD
Pimozide—HTR1A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Pimozide—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.016	0.016	CbGpPWpGaD
Pimozide—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0158	0.0158	CbGpPWpGaD
Pimozide—DRD2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0152	0.0152	CbGpPWpGaD
Pimozide—CHRM2—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0147	0.0147	CbGpPWpGaD
Pimozide—OPRK1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0144	0.0144	CbGpPWpGaD
Pimozide—HTR6—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0142	0.0142	CbGpPWpGaD
Pimozide—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0138	0.0138	CbGpPWpGaD
Pimozide—OPRM1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0122	0.0122	CbGpPWpGaD
Pimozide—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0121	0.0121	CbGpPWpGaD
Pimozide—DRD3—GPCR ligand binding—CXCL11—nasal cavity cancer	0.012	0.012	CbGpPWpGaD
Pimozide—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0119	0.0119	CbGpPWpGaD
Pimozide—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0119	0.0119	CbGpPWpGaD
Pimozide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Pimozide—CALM3—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0106	0.0106	CbGpPWpGaD
Pimozide—HTR1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0105	0.0105	CbGpPWpGaD
Pimozide—CALM1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0102	0.0102	CbGpPWpGaD
Pimozide—CALM2—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0102	0.0102	CbGpPWpGaD
Pimozide—CALM3—Downstream signal transduction—FRS2—nasal cavity cancer	0.00992	0.00992	CbGpPWpGaD
Pimozide—CALM3—Signaling by FGFR—FRS2—nasal cavity cancer	0.00987	0.00987	CbGpPWpGaD
Pimozide—CALM3—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00982	0.00982	CbGpPWpGaD
Pimozide—CALM3—DAP12 signaling—FRS2—nasal cavity cancer	0.00978	0.00978	CbGpPWpGaD
Pimozide—CALM1—Downstream signal transduction—FRS2—nasal cavity cancer	0.0096	0.0096	CbGpPWpGaD
Pimozide—CALM2—Downstream signal transduction—FRS2—nasal cavity cancer	0.0096	0.0096	CbGpPWpGaD
Pimozide—CALM1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00955	0.00955	CbGpPWpGaD
Pimozide—CALM2—Signaling by FGFR—FRS2—nasal cavity cancer	0.00955	0.00955	CbGpPWpGaD
Pimozide—CALM2—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0095	0.0095	CbGpPWpGaD
Pimozide—CALM1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.0095	0.0095	CbGpPWpGaD
Pimozide—CALM2—DAP12 signaling—FRS2—nasal cavity cancer	0.00946	0.00946	CbGpPWpGaD
Pimozide—CALM1—DAP12 signaling—FRS2—nasal cavity cancer	0.00946	0.00946	CbGpPWpGaD
Pimozide—DRD2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00922	0.00922	CbGpPWpGaD
Pimozide—CALM3—DAP12 interactions—FRS2—nasal cavity cancer	0.0092	0.0092	CbGpPWpGaD
Pimozide—CALM3—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0092	0.0092	CbGpPWpGaD
Pimozide—CALM3—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0092	0.0092	CbGpPWpGaD
Pimozide—CALM3—Signaling by EGFR—FRS2—nasal cavity cancer	0.00911	0.00911	CbGpPWpGaD
Pimozide—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00907	0.00907	CbGpPWpGaD
Pimozide—HRH1—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00905	0.00905	CbGpPWpGaD
Pimozide—CALM3—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00903	0.00903	CbGpPWpGaD
Pimozide—CALM3—Signaling by PDGF—FRS2—nasal cavity cancer	0.00899	0.00899	CbGpPWpGaD
Pimozide—CHRM2—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00891	0.00891	CbGpPWpGaD
Pimozide—CALM1—DAP12 interactions—FRS2—nasal cavity cancer	0.0089	0.0089	CbGpPWpGaD
Pimozide—CALM1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0089	0.0089	CbGpPWpGaD
Pimozide—CALM2—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0089	0.0089	CbGpPWpGaD
Pimozide—CALM1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.0089	0.0089	CbGpPWpGaD
Pimozide—CALM2—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.0089	0.0089	CbGpPWpGaD
Pimozide—CALM2—DAP12 interactions—FRS2—nasal cavity cancer	0.0089	0.0089	CbGpPWpGaD
Pimozide—CALM2—Signaling by EGFR—FRS2—nasal cavity cancer	0.00882	0.00882	CbGpPWpGaD
Pimozide—CALM1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00882	0.00882	CbGpPWpGaD
Pimozide—CALM2—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00874	0.00874	CbGpPWpGaD
Pimozide—CALM1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00874	0.00874	CbGpPWpGaD
Pimozide—CALM2—Signaling by PDGF—FRS2—nasal cavity cancer	0.0087	0.0087	CbGpPWpGaD
Pimozide—CALM1—Signaling by PDGF—FRS2—nasal cavity cancer	0.0087	0.0087	CbGpPWpGaD
Pimozide—CALM3—B Cell Activation—FRS2—nasal cavity cancer	0.00851	0.00851	CbGpPWpGaD
Pimozide—CALM2—B Cell Activation—FRS2—nasal cavity cancer	0.00823	0.00823	CbGpPWpGaD
Pimozide—CALM1—B Cell Activation—FRS2—nasal cavity cancer	0.00823	0.00823	CbGpPWpGaD
Pimozide—CALM3—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00815	0.00815	CbGpPWpGaD
Pimozide—OPRK1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00814	0.00814	CbGpPWpGaD
Pimozide—HTR6—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00802	0.00802	CbGpPWpGaD
Pimozide—CALM1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00788	0.00788	CbGpPWpGaD
Pimozide—CALM2—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00788	0.00788	CbGpPWpGaD
Pimozide—OPRK1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00739	0.00739	CbGpPWpGaD
Pimozide—HTR6—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00728	0.00728	CbGpPWpGaD
Pimozide—OPRM1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00688	0.00688	CbGpPWpGaD
Pimozide—DRD3—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00681	0.00681	CbGpPWpGaD
Pimozide—CALM3—Signaling by NGF—FRS2—nasal cavity cancer	0.00626	0.00626	CbGpPWpGaD
Pimozide—OPRM1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00624	0.00624	CbGpPWpGaD
Pimozide—DRD3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00618	0.00618	CbGpPWpGaD
Pimozide—CALM2—Signaling by NGF—FRS2—nasal cavity cancer	0.00606	0.00606	CbGpPWpGaD
Pimozide—CALM1—Signaling by NGF—FRS2—nasal cavity cancer	0.00606	0.00606	CbGpPWpGaD
Pimozide—HTR1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00593	0.00593	CbGpPWpGaD
Pimozide—HTR1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00539	0.00539	CbGpPWpGaD
Pimozide—DRD2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00521	0.00521	CbGpPWpGaD
Pimozide—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00513	0.00513	CbGpPWpGaD
Pimozide—HRH1—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00512	0.00512	CbGpPWpGaD
Pimozide—CHRM2—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00503	0.00503	CbGpPWpGaD
Pimozide—DRD2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00473	0.00473	CbGpPWpGaD
Pimozide—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00466	0.00466	CbGpPWpGaD
Pimozide—HRH1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00465	0.00465	CbGpPWpGaD
Pimozide—CHRM2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00457	0.00457	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00436	0.00436	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—CXCL11—nasal cavity cancer	0.0043	0.0043	CbGpPWpGaD
Pimozide—CALM3—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00386	0.00386	CbGpPWpGaD
Pimozide—CALM2—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00374	0.00374	CbGpPWpGaD
Pimozide—CALM1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00374	0.00374	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00365	0.00365	CbGpPWpGaD
Pimozide—CALM3—Innate Immune System—FRS2—nasal cavity cancer	0.00357	0.00357	CbGpPWpGaD
Pimozide—CALM2—Innate Immune System—FRS2—nasal cavity cancer	0.00346	0.00346	CbGpPWpGaD
Pimozide—CALM1—Innate Immune System—FRS2—nasal cavity cancer	0.00346	0.00346	CbGpPWpGaD
Pimozide—CALM3—Adaptive Immune System—FRS2—nasal cavity cancer	0.00343	0.00343	CbGpPWpGaD
Pimozide—CALM2—Adaptive Immune System—FRS2—nasal cavity cancer	0.00332	0.00332	CbGpPWpGaD
Pimozide—CALM1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00332	0.00332	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—CXCL11—nasal cavity cancer	0.0028	0.0028	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00275	0.00275	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00274	0.00274	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—CXCL11—nasal cavity cancer	0.0027	0.0027	CbGpPWpGaD
Pimozide—OPRK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00257	0.00257	CbGpPWpGaD
Pimozide—HTR6—Signaling Pathways—FRS2—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—CXCL11—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00221	0.00221	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—CXCL11—nasal cavity cancer	0.00221	0.00221	CbGpPWpGaD
Pimozide—OPRM1—Signaling Pathways—FRS2—nasal cavity cancer	0.00217	0.00217	CbGpPWpGaD
Pimozide—DRD3—Signaling Pathways—FRS2—nasal cavity cancer	0.00215	0.00215	CbGpPWpGaD
Pimozide—CALM3—Immune System—FRS2—nasal cavity cancer	0.00208	0.00208	CbGpPWpGaD
Pimozide—CALM2—Immune System—FRS2—nasal cavity cancer	0.00201	0.00201	CbGpPWpGaD
Pimozide—CALM1—Immune System—FRS2—nasal cavity cancer	0.00201	0.00201	CbGpPWpGaD
Pimozide—CALM3—Disease—FRS2—nasal cavity cancer	0.00192	0.00192	CbGpPWpGaD
Pimozide—HTR1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00188	0.00188	CbGpPWpGaD
Pimozide—CALM1—Disease—FRS2—nasal cavity cancer	0.00186	0.00186	CbGpPWpGaD
Pimozide—CALM2—Disease—FRS2—nasal cavity cancer	0.00186	0.00186	CbGpPWpGaD
Pimozide—DRD2—Signaling Pathways—FRS2—nasal cavity cancer	0.00165	0.00165	CbGpPWpGaD
Pimozide—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00162	0.00162	CbGpPWpGaD
Pimozide—HRH1—Signaling Pathways—FRS2—nasal cavity cancer	0.00162	0.00162	CbGpPWpGaD
Pimozide—CHRM2—Signaling Pathways—FRS2—nasal cavity cancer	0.00159	0.00159	CbGpPWpGaD
Pimozide—CALM3—Signaling Pathways—FRS2—nasal cavity cancer	0.00135	0.00135	CbGpPWpGaD
Pimozide—CALM2—Signaling Pathways—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Pimozide—CALM1—Signaling Pathways—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
